Clinical trials: Oral Cavity Carcinoma
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
The purpose of this study is to determine the safety, tolerability, and the highest dose of GC4419 that can be given to patients with squamous cell cancer of the head and neck who are receiving standard radiation therapy and…
- Trial name
- NCT01921426
- Testing
- GC4419
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Galera Therapeutics, Inc.
Bladder Cancer, Recurrent Bladder Cancer
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
The purpose of this study is to assess the effectiveness of erdafitinib in people with non-muscle invasive bladder cancer (NMIBC) that has come back after standard treatment, such as Bacillus Calmette-Guerin (BCG) or chemotherapy…
- Conditions
- Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation
- Trial name
- NCT04917809
- Testing
- Erdafitinib
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Cardiovascular Complications
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure.
- Conditions
- Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01096381
- Testing
- laboratory biomarker analysis, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Bladder Cancer, Brain and Central Nervous System Tumors
High-dose ICE With Amifostine
The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and…
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor
- Trial name
- NCT00003657
- Testing
- filgrastim, Amifostine, Carboplatin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
Oral Squamous Cell Carcinoma
Toluidine Blue Versus Frozen Sections for Assessment of Tumor Margins in Oral Squamous Cell Carcinoma
The purpose of this study is to test the accuracy of toluidine blue in the assessment of intraoperative tumor margin after excision of oral squamous cell carcinoma(OSCC)in comparison to H\&E stain on frozen section.
- Trial name
- NCT03554967
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University
Oral Squamous Cell Carcinoma, Carcinoma of Buccal Mucosa
Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study
This is a phase II randomized clinical trial to study the effect of COX-2 inhibitor Celecoxib and EGFR tyrosine kinase inhibitor Erlotinib alone or in combination on molecular markers of apoptosis and angiogenesis.
- Conditions
- Oral Squamous Cell Carcinoma, Carcinoma of Buccal Mucosa, Tongue Cancers, Head and Neck Cancers
- Trial name
- ERLO-XIB (NCT02748707)
- Testing
- Arm1, Arm 2, Arm 3
- Where
- India
- Volunteers
- 64 people
- Sponsor
- Tata Memorial Hospital
Oral Cancer, Osteosarcoma
Quantitative Margin Assessment Using High-resolution Positron Emission Tomography - Computed Tomograhy
The primary endpoint is the assessment of the clinical value of a novel high-resolution mobile PET-CT scanner for intraoperative margin assessment in oral squamous cell carcinoma, soft tissue sarcoma and osteosarcoma surgery.
- Conditions
- Oral Cancer, Osteosarcoma, Soft Tissue Sarcoma, Oral Squamous Cell Carcinoma (OSCC)
- Trial name
- qMAP (NCT06726512)
- Testing
- XEOS AURA 10
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- University Medical Center Groningen
Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
This randomized phase II trial studies how well vandetanib works in preventing head and neck cancer in patients with precancerous head and neck lesions. Chemoprevention is the use of certain drugs to keep cancer from forming.
- Conditions
- Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma, Precancerous Condition
- Trial name
- NCT01414426
- Testing
- vandetanib, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Chicago
Neck Dislocation, Oral Cancer
Submandibular Gland Preservation in Neck Dissection
Trial design: a randomized controlled trial. Eligibility criteria for participants: patients with primary early stage oral squamous cell carcinoma. Exclusion criteria: cancer of the floor of the mouth.
- Trial name
- NCT03385720
- Testing
- modified neck dissection, traditional neck dissection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guang-Yan Yu
Gastric Neoplasm
Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2)
To evaluate the survival benefit of adjuvant chemotherapy after curative resection with D2 or greater lymph node dissection in T3-4 gastric cancer patients.
- Trial name
- NCT00147147
- Testing
- Gastrectomy with D2 or greater lymph node dissection, Gastrectomy+ chemotherapy
- Where
- Japan
- Volunteers
- 280 people
- Sponsor
- Japan Clinical Oncology Group
Hepatocellular Carcinoma
Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma
The purpose of this study is to evaluate the Safety and Pharmacokinetics of Oral Artesunate in patients with advanced hepatocellular carcinoma (HCC)
- Trial name
- DESPARTH (NCT02304289)
- Testing
- Artesunate
- Where
- Belgium
- Volunteers
- 2 people
- Sponsor
- University Hospital, Ghent
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
This phase II trial studies how well giving temsirolimus together with cetuximab works compared to temsirolimus alone in treating patients with recurrent and/or metastatic head and neck cancer who did not respond to previous…
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- MAESTRO HN (NCT01256385)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 24 sites in United States, China
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
HNSCC, Head and Neck Cancer
Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer
This study is being done to see whether Avmacol®, a dietary supplement made from broccoli sprout and seed extract powder, induces changes in inner cheek cells that may be protective against environmental toxins such as tobacco.
- Conditions
- HNSCC, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Tobacco-Related Carcinoma
- Trial name
- NCT03182959
- Testing
- Avmacol®
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arizona
Head and Neck Cancers- Squamous Cell, Head and Neck Cancer
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
The goal of this clinical trial is to assess the safety and tolerability of a virus replicon particle (VRP) encapsulated saRNA encoding IL-12 when injected into in head and neck cancer patients.
- Conditions
- Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors, HNSCC
- Trial name
- NCT06736379
- Testing
- VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- VLP Therapeutics
Carcinoma, Non-Small Cell, Neoplasm Metastasis
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor.
- Trial name
- NCT00728390
- Testing
- PF-00299804
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Pfizer
Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer
Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810
This project intends to make a study of personalized medicine evaluation system establishment for liver cancer, gastric cancer and nasopharynx cancer to provide strong support for the development of Precision Medicine and…
- Trial name
- NCT03260179
- Testing
- AL3810
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00939627
- Testing
- cetuximab, sorafenib tosylate, laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Fenretinide in Treating Patients With Leukoplakia of the Mouth
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of or treat early cancer. Fenretinide may be an effective drug in treating leukoplakia.
- Trial name
- NCT00004161
- Testing
- fenretinide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Adenoid Cystic Carcinoma
A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
This is a non-randomized, phase II, open label study of Apatinib Mesylate in patients with Head and neck recurrent/metastatic adenoid cystic carcinoma (ACC).
- Trial name
- NCT02775370
- Testing
- Apatinib Mesylate
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.